239 related articles for article (PubMed ID: 31722348)
21. Evidence of mast cell activation and leukotriene release after mannitol inhalation.
Brannan JD; Gulliksson M; Anderson SD; Chew N; Kumlin M
Eur Respir J; 2003 Sep; 22(3):491-6. PubMed ID: 14516140
[TBL] [Abstract][Full Text] [Related]
22. Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
Cahill KN; Wu P; Milne GL; Amin T; Singer J; Murphy K; Lewis E; Gapko D; Boyce JA; Buchheit KM; Laidlaw TM
J Allergy Clin Immunol; 2022 Jul; 150(1):170-177.e6. PubMed ID: 35026207
[TBL] [Abstract][Full Text] [Related]
23. Mast cell activation syndrome: a review.
Frieri M; Patel R; Celestin J
Curr Allergy Asthma Rep; 2013 Feb; 13(1):27-32. PubMed ID: 23179866
[TBL] [Abstract][Full Text] [Related]
24. Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects.
Vos BJ; van der Veer E; van Voorst Vader PC; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; de Monchy JG; van Doormaal JJ; Oude Elberink JN
J Allergy Clin Immunol; 2015 Mar; 135(3):792-8. PubMed ID: 25129675
[TBL] [Abstract][Full Text] [Related]
25. Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma.
Bochenek G; Nizankowska E; Gielicz A; Swierczyńska M; Szczeklik A
Thorax; 2004 Jun; 59(6):459-64. PubMed ID: 15170023
[TBL] [Abstract][Full Text] [Related]
26. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Rubin P; Cohn J; White MV; Igarashi Y; Kaliner MA; Drazen JM
J Allergy Clin Immunol; 1994 Dec; 94(6 Pt 1):1046-56. PubMed ID: 7798537
[TBL] [Abstract][Full Text] [Related]
27. Divergent PGD
Butterfield JH; Singh RJ
Prostaglandins Other Lipid Mediat; 2021 Aug; 155():106563. PubMed ID: 34029712
[TBL] [Abstract][Full Text] [Related]
28. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
[TBL] [Abstract][Full Text] [Related]
29. Serum tryptase level is a better predictor of systemic side effects than prostaglandin D2 metabolites during venom immunotherapy in children.
Cichocka-Jarosz E; Sanak M; Szczeklik A; Brzyski P; Gielicz A; Pietrzyk JJ
J Investig Allergol Clin Immunol; 2011; 21(4):260-9. PubMed ID: 21721371
[TBL] [Abstract][Full Text] [Related]
30. Increases in urinary 9alpha,11beta-prostaglandin f2 indicate mast cell activation in wine-induced asthma.
Misso NL; Aggarwal S; Thompson PJ; Vally H
Int Arch Allergy Immunol; 2009; 149(2):127-32. PubMed ID: 19127069
[TBL] [Abstract][Full Text] [Related]
31. How good are mast cell mediators?
Weiler CR
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):410-411. PubMed ID: 34303837
[No Abstract] [Full Text] [Related]
32. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.
Hamilton MJ
Immunol Allergy Clin North Am; 2018 Aug; 38(3):469-481. PubMed ID: 30007464
[TBL] [Abstract][Full Text] [Related]
33. Determination of plasma heparin level improves identification of systemic mast cell activation disease.
Vysniauskaite M; Hertfelder HJ; Oldenburg J; Dreßen P; Brettner S; Homann J; Molderings GJ
PLoS One; 2015; 10(4):e0124912. PubMed ID: 25909362
[TBL] [Abstract][Full Text] [Related]
34. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.
van Doormaal JJ; van der Veer E; van Voorst Vader PC; Kluin PM; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; Oude Elberink JN; de Monchy JG
Allergy; 2012 May; 67(5):683-90. PubMed ID: 22435702
[TBL] [Abstract][Full Text] [Related]
35. Biochemical diagnosis of systemic mast cell disorders.
Roberts LJ; Oates JA
J Invest Dermatol; 1991 Mar; 96(3 Suppl):19S-24S; discussion 24S-25S; 60S-65S. PubMed ID: 16799604
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis.
Kurosawa M; Amano H; Kanbe N; Akimoto S; Takeuchi Y; Yamashita T; Hashimoto T; Kurimoto F; Miyachi Y
J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 2):S25-32. PubMed ID: 9440541
[TBL] [Abstract][Full Text] [Related]
37. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria.
Valent P; Horny HP; Triggiani M; Arock M
Int Arch Allergy Immunol; 2011; 156(2):119-27. PubMed ID: 21576982
[TBL] [Abstract][Full Text] [Related]
38. Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients.
Di Lorenzo G; Pacor ML; Vignola AM; Profita M; Esposito-Pellitteri M; Biasi D; Corrocher R; Caruso C
Allergy; 2002 Dec; 57(12):1180-6. PubMed ID: 12464047
[TBL] [Abstract][Full Text] [Related]
39. Human mast cell tryptase in biology and medicine.
Vitte J
Mol Immunol; 2015 Jan; 63(1):18-24. PubMed ID: 24793463
[TBL] [Abstract][Full Text] [Related]
40. Hymenoptera Allergy and Mast Cell Activation Syndromes.
Bonadonna P; Bonifacio M; Lombardo C; Zanotti R
Curr Allergy Asthma Rep; 2016 Jan; 16(1):5. PubMed ID: 26714690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
